Detalles de la búsqueda
1.
Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.
Br J Clin Pharmacol
; 78(5): 1067-75, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24910925
2.
Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.
Clin Endocrinol (Oxf)
; 77(1): 132-8, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22248037
3.
Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer.
Pharmacogenet Genomics
; 21(6): 341-3, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21317830
4.
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy.
Arch Endocrinol Metab
; 62(2): 149-156, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29641738
5.
Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.
J Clin Endocrinol Metab
; 101(7): 2692-700, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27023446
6.
Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm.
J Thyroid Res
; 2013: 398194, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24455413
7.
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
Arch. endocrinol. metab. (Online)
; 62(2): 149-156, Mar.-Apr. 2018. tab
Artículo
en Inglés
| LILACS | ID: biblio-887653
Resultados
1 -
7
de 7
1
Próxima >
>>